Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial-Reference-Cited by-同舟云学术

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Published:2017-12-21 Issue:11 Volume:66 Page:1794-1797
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Taiwo Babafemi O¹,Marconi Vincent C²,Berzins Baiba¹,Moser Carlee B³,Nyaku Amesika N⁴,Fichtenbaum Carl J⁵,Benson Constance A⁶,Wilkin Timothy⁷,Koletar Susan L⁸,Colasanti Jonathan²,Acosta Edward P⁹,Li Jonathan Z¹⁰,Sax Paul E¹¹

Affiliation:

1. Division of Infectious Diseases, Northwestern University, Chicago, Illinois

2. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia

3. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts

4. Division of Infectious Diseases, Rutgers University, Newark, New Jersey

5. Department of Internal Medicine, University of Cincinnati, Ohio

6. Division of Infectious Diseases and Global Public Health, University of California, San Diego

7. Division of Infectious Diseases, Weill Cornell Medicine, New York, New York

8. Division of Infectious Diseases, The Ohio State University, Columbus

9. Department of Pharmacology and Toxicology, University of Alabama at Birmingham

10. Division of Infectious Diseases, Brigham and Women’s Hospital

11. Harvard Medical School, Boston, Massachusetts

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/66/11/1794/25084312/cix1131.pdf

Reference12 articles.

1. Libre JM , HungCC, BrinsonC, et al Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI);13–16 February 2017, Seattle. Abstract 44LB

2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial;Margolis;Lancet,2017

3. Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M);Di Giambenedetto;J Antimicrob Chemother,2017

4. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial;Arribas;Lancet Infect Dis,2015

5. Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial;Pulido;Clin Infect Dis,2017

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation;Viruses;2024-08-30

2. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years;Contemporary Clinical Trials;2024-07

3. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04

4. Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review;2024-01-07

5. Efficacy and safety of raltegravir plus lamivudine maintenance therapy;Journal of Antimicrobial Chemotherapy;2023-12-01